Track market-moving stories before they get noisy

Medpace (MEDP - Free Report) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.1 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +4.17%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $3.74 per share when it actually produced earnings of $4.28, delivering a surprise of +14.44%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Medpace, which belongs to the Zacks Medical Services industry, posted revenues of $707.33 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.12%. This compares to year-ago revenues of $603.31 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Medpace shares have lost about 5.3% since the beginning of the year versus the S&P 500's gain of 9.7%.

What's Next for Medpace?While Medpace has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Medpace was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.22 on $694.23 million in revenues for the coming quarter and $17.04 on $2.79 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Avantor, Inc. (AVTR - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on July 29.

This company is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of -20.8%. The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level.

Avantor, Inc.'s revenues are expected to be $1.62 billion, down 3.5% from the year-ago quarter.

Key Takeaways Medpace's $2.93B backlog supports revenue visibility, with $1.9B-$1.94B expected to convert over 12 months.MEDP's metabolic programs help stabilize backlog as oncology and cardiovascular see higher cancellations.MEDP faces softer proposal activity and a 0.88X book-to-bill ratio, tempering near-term growth signals. Medpace Holdings, Inc. (MEDP - Free Report) has a near-term setup defined less by headline growth and more by the quality of its backlog. Revenue visibility remains meaningful, but booking momentum is not yet sending a clean reacceleration signal.

The company still has several supports, including stable margins, liquidity and metabolic demand. The issue for investors is whether cancellations and softer requests for proposals keep that visibility from turning into faster growth.

Here’s a look at Medpace’s stock performance over the past 12 months.

Image Source: Zacks Investment Research

How Medpace Makes Its Clinical Model WorkMedpace operates as a global, full-service clinical contract research organization supporting Phase I-IV drug and device development. Its services include protocol and project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, submission support, bioanalytical labs and medical imaging.

The model is centralized and managed as one full-service platform, which helps keep study execution consistent across North America, Europe and Asia. Medpace has particular depth in oncology, metabolic disease, cardiology, central nervous system, antiviral and anti-infective work.

Client mix is another defining feature. Small biopharma accounted for 82% of fiscal 2025 revenues, while mid-sized biopharma represented 13%, leaving MEDP closely tied to emerging and development-stage sponsors.

IQVIA Holdings Inc. (IQV - Free Report) gives investors another large-scale CRO reference point because it provides clinical research services, commercial insights and healthcare intelligence to life sciences customers. Charles River Laboratories International, Inc. (CRL - Free Report) sits in an adjacent contract research area, with drug discovery, non-clinical development and safety testing exposure.

MEDP Backlog Still Supports 2026 RevenueBacklog remains the clearest source of revenue continuity. Medpace ended March 31, 2026, with backlog of $2.93 billion, up 2.9% from the year-ago period.

Management projects roughly $1.9 billion-$1.94 billion of backlog will convert into revenues over the next 12 months. That conversion base gives the company a bridge into 2026 even as net new business awards of $618.4 million produced a net book-to-bill ratio of 0.88X in the first quarter.

The distinction matters. Backlog supports visibility, but a sub-1.0X book-to-bill means awards did not fully replenish quarterly revenues. For now, the backlog points to continuity rather than proof that growth is ready to accelerate.

Take a look at Medpace’s sales multiple over the last five years.

Image Source: Zacks Investment Research

Medpace Finds Stability in Metabolic DemandMetabolic and GLP-1 programs remain an important stabilizer. These programs have historically carried lower cancellation rates than some other tracked therapeutic areas, which supports backlog quality and utilization.

That exposure is valuable because oncology and cardiovascular programs have been more cancellation-prone. In the first quarter of 2026, metabolic revenues reached $237.6 million, exceeding oncology revenues of $201.2 million and making metabolic the largest disclosed therapeutic area by revenue.

The opportunity is not without limits. New metabolic opportunities could face saturation or price sensitivity, but durable in-flight work still helps MEDP absorb pressure elsewhere in the portfolio.

MEDP Faces the Drag From CancellationsCancellations remain the main offset to the backlog story. First-quarter cancellations reached their highest level in more than a year, with oncology and cardiovascular programs the largest contributors.

The demand funnel also looks uneven. Requests for proposals declined sequentially and year over year, while the first-quarter book-to-bill ratio stayed below 1.0X.

Initial award notifications and win rates were stronger, which helps the pipeline narrative. Still, many awards remain in pre-backlog, and typical lags of three to five quarters before program starts limit the immediate revenue benefit.

Medpace Signals Matter for Patient InvestorsThe bottom line is that MEDP offers a balanced signal set. Backlog conversion, stable profitability and metabolic exposure support patience, but cancellations, softer proposal activity and delayed program starts keep the near-term outlook measured.

The stock currently carries a Zacks Rank #3 (Hold), which points to more balanced short-term earnings estimate picture. Its Style Scores show a Growth Score of A, Value Score of D, Momentum Score of C and VGM Score of B. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

That mix fits the current debate. The Growth Score of A and VGM Score of B point to attractive growth traits and a favorable combined style profile, while the Value Score of D suggests valuation support is less clear. For investors, MEDP’s next signal is likely to come from whether backlog quality and awards can outpace cancellations without pressuring margins.